CD274 and melanoma: However, the question of whether PD‐1/PD‐L1 inhibitors hold efficacy for PD‐L1 low expression (CPS < 1 or TPS < 1%) patients has remained unanswered, a query that has garnered heightened attention in other malignancies such as melanoma, renal cell carcinoma, non‐small cell lung cancer (NSCLC), and esophageal carcinomas.19, 20